Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InMed Pharmaceuticals (INM) Free Cash Flow (2021 - 2025)

Historic Free Cash Flow for InMed Pharmaceuticals (INM) over the last 5 years, with Q3 2025 value amounting to -$1.6 million.

  • InMed Pharmaceuticals' Free Cash Flow rose 1199.87% to -$1.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$7.5 million, marking a year-over-year decrease of 1369.79%. This contributed to the annual value of -$7.8 million for FY2025, which is 1103.38% down from last year.
  • As of Q3 2025, InMed Pharmaceuticals' Free Cash Flow stood at -$1.6 million, which was up 1199.87% from -$1.8 million recorded in Q2 2025.
  • InMed Pharmaceuticals' 5-year Free Cash Flow high stood at -$689750.0 for Q2 2023, and its period low was -$5.4 million during Q1 2022.
  • Moreover, its 5-year median value for Free Cash Flow was -$1.9 million (2024), whereas its average is -$2.3 million.
  • As far as peak fluctuations go, InMed Pharmaceuticals' Free Cash Flow soared by 8295.76% in 2023, and later plummeted by 7281.07% in 2025.
  • InMed Pharmaceuticals' Free Cash Flow (Quarter) stood at -$3.3 million in 2021, then rose by 18.26% to -$2.7 million in 2022, then skyrocketed by 31.88% to -$1.8 million in 2023, then crashed by 35.39% to -$2.5 million in 2024, then soared by 35.75% to -$1.6 million in 2025.
  • Its Free Cash Flow stands at -$1.6 million for Q3 2025, versus -$1.8 million for Q2 2025 and -$1.7 million for Q1 2025.